Reduction in venous thromboembolism by agents affecting platelet function.
D000328:Adult; D000368:Aged; D001178:Arthroplasty; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D002858:Chromium Alloys; D003911:Dextrans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004176:Dipyridamole / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006615:Hip / Q000601:surgery; D006801:Humans; D007595:Joint Prosthesis; D008297:Male; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control; D014680:Veins; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D002858:Chromium Alloys; D003911:Dextrans; D014859:Warfarin; D004176:Dipyridamole; D001241:Aspirin